157 results
8-K
EX-99.1
BAX
Baxter International Inc.
6 Jul 23
Regulation FD Disclosure
8:30am
understand their perspectives on a variety of relevant topics, including: Company strategy and performance Board oversight of risk and capital
8-K
EX-3.1
BAX
Baxter International Inc.
9 May 23
Baxter Signs Definitive Agreement to Divest its BioPharma Solutions Business to
8:42am
Executive Officer may be necessary or desirable, subject to the oversight of the Board of Directors. Unless otherwise designated by the Board of Directors
8-K
EX-3.2
luu25l qy7swj2z
6 May 22
Material Modifications to Rights of Security Holders
4:57pm
8-K
EX-99.2
60m8wp36xcf8e nr
13 Dec 21
Creating ~$15 Billion Global Medtech Leader
4:46pm
8-K
EX-1.01
1wkx3c6
17 Nov 21
Entry into a Material Definitive Agreement
8:07am
8-K
EX-99.1
bwk6ptvm1utnh
18 Oct 21
October 2021 Baxter International Inc. Fall Shareholder Engagement
8:35am
8-K
EX-99.1
5qdb2x5u2erfzasjei
29 Apr 21
Other Events
7:36am
8-K
EX-99.1
sgmh jawr0du
16 Feb 21
Baxter Appoints DR. David Wilkes to Its Board and Albert Stroucken As Lead Independent Director
4:35pm